Immatics NV (IMTX)
10.81
-0.27
(-2.44%)
USD |
NASDAQ |
May 16, 16:00
10.82
+0.01
(+0.09%)
After-Hours: 20:00
Immatics Research and Development Expense (Quarterly): 34.88M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 34.88M |
| December 31, 2023 | 35.83M |
| September 30, 2023 | 33.21M |
| June 30, 2023 | 29.79M |
| March 31, 2023 | 29.62M |
| December 31, 2022 | 28.47M |
| September 30, 2022 | 28.78M |
| June 30, 2022 | 26.86M |
| March 31, 2022 | 28.21M |
| December 31, 2021 | 26.26M |
| Date | Value |
|---|---|
| September 30, 2021 | 25.03M |
| June 30, 2021 | 24.51M |
| March 31, 2021 | 27.77M |
| December 31, 2020 | 24.86M |
| September 30, 2020 | 20.45M |
| June 30, 2020 | 18.18M |
| March 31, 2020 | 13.51M |
| December 31, 2019 | 13.43M |
| September 30, 2019 | 11.38M |
| June 30, 2019 | 10.94M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
10.94M
Minimum
Jun 2019
35.83M
Maximum
Dec 2023
24.60M
Average
26.56M
Median
Research and Development Expense (Quarterly) Benchmarks
| MorphoSys AG | 86.49M |
| Affimed NV | 20.09M |
| InflaRx NV | 7.931M |
| BioNTech SE | 551.24M |
| CureVac NV | 35.93M |